US Stock Details

Get in-depth insights on US stocks, including fundamentals, financials, shareholding, peer comparison, and performance. Track key metrics, price trends, and market sentiment for informed decisions. Stay ahead with expert analysis and data-driven strategies at Motilal Oswal.

Elutia Inc

us-stock
To Invest in {{usstockname}}
us-stock
$0.67 0.0008(0.08%) ELUT at 04 Dec 2025 04:30 PM Medical Devices
Lowest Today 0.64
Highest Today 0.699
Today’s Open 0.699
Prev. Close 0.645
52 Week High 4.84
52 Week Low 0.58
Day’s Range: Low 0.64 High 0.699
52-Week Range: Low 0.58 High 4.84
1 day return -
1 Week return +6.49
1 month return -30.69
3 month return -68.1
6 month return -66.6
1 year return -87.02
3 year return -82.24
5 year return -95.59
10 year return -

Institutional Holdings

Market Status

Strong Buy: 2

Buy: 0

Hold: 0

Sell: 0

Strong Sell: 0

Fundamentals

Market Cap 27.54 M

PB Ratio 0.0

PE Ratio 0.0

Enterprise Value 50.55 M

Total Assets 36.13 M

Volume 284548

Company Financials

Annual Revenue FY23:50795000 50.8M, FY22:49187000 49.2M, FY21:47390000 47.4M, FY20:42682000 42.7M, FY19:42901000 42.9M

Annual Profit FY23:19576000 19.6M, FY22:19222000 19.2M, FY21:19022000 19.0M, FY20:20561000 20.6M, FY19:19768000 19.8M

Annual Net worth FY23:-33782000 -33.8M, FY22:-32897000 -32.9M, FY21:-24832000 -24.8M, FY20:-21825000 -21.8M, FY19:-11939000 -11.9M

Quarterly Revenue Q3/2025:3323000 3.3M, Q2/2025:6263000 6.3M, Q1/2025:6030000 6.0M, Q3/2024:5922000 5.9M, Q2/2024:6291000 6.3M

Quarterly Profit Q3/2025:1853000 1.9M, Q2/2025:3058000 3.1M, Q1/2025:2457000 2.5M, Q3/2024:2741000 2.7M, Q2/2024:2799000 2.8M

Quarterly Net worth Q3/2025:-3868000 -3.9M, Q2/2025:-9610000 -9.6M, Q1/2025:-3933000 -3.9M, Q3/2024:1286000 1.3M, Q2/2024:-28180000 -28.2M

Fund house & investment objective

Company Information Elutia Inc., a commercial-stage company, develops and commercializes drug-eluting biologics products for neurostimulation and breast reconstruction in the United States. It operates in three segments: Device Protection, Women's Health, and Cardiovascular. The company offers EluPro, which is used to accommodate cardiac implantable electronic devices, such as pacemakers and internal defibrillators; and CanGaroo, which mitigates complications derived from implantable electronic devices and shortcomings of synthetic envelopes. It also provides ProxiCor for cardiac tissue repair and pericardial closure; Tyke, an extracellular material that is used in the repair of cardiac structures for neonate and infant patients; and VasCure, a patch material used to repair or reconstruct the peripheral vasculature. In addition, the company offers SimpliDerm, which uses human acellular dermal matrices for tissue repair and reconstruction in various applications, such as sports medicine, hernia repair, trauma reconstruction, and breast reconstruction. It serves hospitals and healthcare facilities through its direct sales force, commercial partners, independent sales agents, and distributors. The company was formerly known as Aziyo Biologics, Inc. and changed its name to Elutia Inc. in September 2023. Elutia Inc. was incorporated in 2015 and is headquartered in Silver Spring, Maryland.

Organisation Medical Devices

Employees 51

Industry Medical Devices

CEO Dr. C. Randal Mills Ph.D.

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right